Real estate stocks fluctuated lower, with Gorgeous Family, Qixia Construction, Everbright Jiabao and Tiandiyuan falling more than 5%, while urban construction development and Chongqing development followed suit.The Hang Seng Index of Hong Kong stocks opened lower by 0.78%, the index of state-owned enterprises fell by 0.88%, and the branch index opened lower by 1.01%.The Shenzhen Stock Exchange terminated the audit of four bond projects with a total amount of 5.879 billion yuan. On December 13, the Shenzhen Stock Exchange recently terminated the audit of four bond projects with a total amount of 5.879 billion yuan, and the varieties were small public offerings and private placements.
Solar energy and other new companies have set up photovoltaic power generation equipment business. The enterprise search APP shows that recently, China Energy Saving Ledebao Solar Technology (Delingha) Co., Ltd. was established, with Du Hu as the legal representative and a registered capital of 1 million yuan. Its business scope includes: sales of solar thermal utilization equipment; Lease of photovoltaic power generation equipment; Ecological restoration and ecological protection services, etc. Enterprise investigation shows that the company is jointly owned by China Energy Saving Solar Technology Co., Ltd. and Qinghai Laidebao New Materials Co., Ltd., a wholly-owned subsidiary of solar energy.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.Li Tie was sentenced to 20 years. On December 13, 2024, the Intermediate People's Court of Xianning City, Hubei Province publicly pronounced the case of Li Tie, the former head coach of China National Men's Football Team. Li Tie was sentenced to 20 years' imprisonment for accepting bribes, bribery, unit bribery, bribery of non-state staff and bribery of non-state staff. (CCTV News)
Tik Tok bean bag concept stocks opened lower and went higher, three-dimensional communication rose daily, Zhejiang-Wenzhou Internet, Zhangyue Technology and Guangbo shares rose sharply.List of stock repurchases of Hong Kong stocks: 43 stocks were repurchased by the company. On December 12, a total of 43 Hong Kong stocks were repurchased by the company, and the repurchase amount of 8 stocks exceeded HK$ 10 million. Among them, Tencent Holdings, AIA and Samsonite have the largest repurchase amounts, with the company repurchasing HK$ 704 million, HK$ 61,711,300 and HK$ 34,247,500 respectively. As of December 12, 274 Hong Kong stocks have been repurchased by the company this year, and the cumulative repurchase amount of 62 stocks during the year exceeded HK$ 100 million. Among them, Tencent Holdings, HSBC Holdings and AIA have the largest cumulative repurchase amount during the year, with the company repurchasing HK$ 104.602 billion, HK$ 40.706 billion and HK$ 31.059 billion respectively.Kangxinuo said on the interactive platform that the company is promoting the research and development of a variety of innovative vaccines, submitting applications for related matters in accordance with the guiding principles of CDE, and actively communicating and reporting.
Strategy guide
12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide
Strategy guide 12-14
Strategy guide
12-14